PegLeg2na
Well-Known Member
- Joined
- Jul 16, 2011
- Messages
- 1,185
- Reaction score
- 0
Edit Oct. 16, 2011: Unbolded everything and removed "personal comments"!
I’m probably going to get a lot of crap for posting this and “scaring” people, but I’ve been thinking about doing this for a while now. I should have done this earlier. My goal is NOT to scare you- so if you’ve already had the shot, PLEASE don’t read this. My goal is to help those who haven’t had the shot make an informed decision about getting it. Here are all the FACTS that your doctor may or may not tell you. I’m a librarian and this information is the result of long hours of research. I’ve given links to all my (online) sources so you can read the information first hand, but it’s all here, too.
Approved vaccines for the U.S.: https://www.cdc.gov/flu/protect/vaccine/vaccines.htm
-FLUZONE: “Pregnancy Category B: A developmental and reproductive toxicity study has been performed in female rabbits at a dose approximately 20 times the human dose (on a mg/kg basis) and has revealed no evidence of impaired female fertility or harm to the fetus due to Fluzone Intradermal. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Fluzone Intradermal should be used during pregnancy only if clearly needed.” https://www.fda.gov/downloads/biologicsbloodvaccines/.../ucm195479.pdf
-FLUVIRIN: “Pregnancy Cetgory C: Animal reproduction studies have not been conducted with FLUVIRIN. It is also not known whether FLUVIRIN can cause fetal harm when administered to pregnant women or can affect reproduction capacity. FLUVIRIN should be given to pregnant women only if clearly needed.” https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm123694.pdf
-FLUARIX: “Pregnancy Category B: A reproductive and developmental toxicity study has been performed in female rats at a dose approximately 56 times the human dose (on a mg/kg basis) and revealed no evidence of impaired female fertility or harm to the fetus due to FLUARIX. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, FLUARIX should be given to a pregnant woman only if clearly needed.
In a reproductive and developmental toxicity study, the effect of FLUARIX on embryo-fetal and pre-weaning development was evaluated in pregnant rats. Animals were administered FLUARIX by intramuscular injection once prior to gestation, and during the period of organogenesis (gestation days 6, 8, 11, and 15), 0.1 mL/rat/occasion (approximately 56-fold excess relative to the projected human dose on a body weight basis). No adverse effects on mating, female fertility, pregnancy, parturition, lactation parameters, and embryo-fetal or pre-weaning development were observed. There were no vaccine-related fetal malformations or other evidence of teratogenesis.
Pregnancy Registry: GlaxoSmithKline maintains a surveillance registry to collect data on pregnancy outcomes and newborn health status outcomes following vaccination with FLUARIX during pregnancy. Women who receive FLUARIX during pregnancy should be encouraged to contact GlaxoSmithKline directly or their healthcare provider should contact GlaxoSmithKline by calling 1-888-452-9622.” https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220624.pdf
-FLULAVAL: Pregnancy Category B: A reproductive and developmental toxicity study has been performed in female rats at a dose approximately 56 times the human dose (on a mg/kg basis) and revealed no evidence of impaired female fertility or harm to the fetus due to FLULAVAL. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, FLULAVAL should be given to a pregnant woman only if clearly needed.
In a reproductive and developmental toxicity study, the effect of FLULAVAL on embryo-fetal and pre-weaning development was evaluated in pregnant rats. Animals were administered FLULAVAL by intramuscular injection once prior to gestation, and during the period of organogenesis (gestation days 6, 8, 11, and 15), 0.1 mL/rat/occasion (approximately 56-fold excess relative to the projected human dose on a body weight basis). No adverse effects on mating, female fertility, pregnancy, parturition, lactation parameters, and embryo-fetal or pre-weaning development were observed. There were no vaccine-related fetal malformations or other evidence of teratogenesis.
Pregnancy Registry: GlaxoSmithKline maintains a surveillance registry to collect data on pregnancy outcomes and newborn health status outcomes following vaccination with FLULAVAL during pregnancy. Women who receive FLULAVAL during pregnancy should be encouraged to contact GlaxoSmithKline directly or their healthcare provider should contact GlaxoSmithKline by calling 1-888-452-9622.” https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112904.pdf
-AFLURIA: “Pregnancy Category C: Animal reproduction studies have not been conducted with AFLURIA. It is also not known whether AFLURIA can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. AFLURIA should be given to a pregnant woman only if clearly needed.” https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm220730.pdf
-FLUMISTA: “Pregnancy Category C: Animal reproduction studies have not been conducted with FluMist. It is not known whether FluMist can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. FluMist should be given to a pregnant woman only if clearly needed. The effect of the vaccine on embryo-fetal and pre-weaning development was evaluated in a developmental toxicity study using pregnant rats receiving the frozen formulation. Groups of animals were administered the vaccine either once (during the period of organogenesis on gestation day 6) or twice (prior to gestation and during the period of organogenesis on gestation day 6), 250 microliter/rat/occasion (approximately 110-140 human dose equivalents), by intranasal instillation. No adverse effects on pregnancy, parturition, lactation, embryo-fetal or pre-weaning development were observed. There were no vaccine-related fetal malformations or other evidence of teratogenesis noted in this study.” https://www.medimmune.com/pdf/products/flumist_pi.pdf
Approved vaccines for the U.K.:
-PANDEMRIX: Pregnancy and lactation: Pandemrix has been administered to women in each trimester of pregnancy. Information on outcomes from estimated more than 200,000 women who have been vaccinated during pregnancy is currently limited. There was no evidence of an increased risk of adverse outcomes in over 100 pregnancies that were followed in a prospective clinical study.
Animal studies with Pandemrix do not indicate reproductive toxicity (see section 5.3).
Data from pregnant women vaccinated with different inactivated non-adjuvanted seasonal vaccines do not suggest malformations or fetal or neonatal toxicity.
Pandemrix may be administered in lactating women.” https://www.emea.europa.eu/docs/en_...duct_Information/human/000832/WC500038121.pdf
-FOCETRIA: Pregnancy and lactation: It is estimated that more than 90,000 women have been vaccinated during pregnancy with Focetria H1N1v. However information on the number of outcomes is currently limited. Preliminary data on outcomes from spontaneously reported events and ongoing post-marketing studies (pregnancy registry and prospective interventional study) do not suggest direct or indirect harmful effects with respect to pregnancy.
Data from pregnant women vaccinated with different inactivated non-adjuvanted seasonal vaccines do not suggest malformations or fetal or neonatal toxicity. An animal study with H5N1 mock-up vaccine did not indicate reproductive toxicity (see section 5.3). The use of Focetria during pregnancy has to take into account official recommendations. Focetria may be administered to lactacting women. https://www.ema.europa.eu/docs/en_G...duct_Information/human/000710/WC500023749.pdf
Peer-reviewed articles related to fetal harm and the vaccine OR showing no relationship between the two:
Moro, Pedro L. et al. “Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System”. American Journal of Obstetrics & Gynecology (2011).
ABSTRACT:
OBJECTIVE: The objective of the study was to evaluate and summarize reports to the Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting system, in pregnant women who received influenza A (H1N1) 2009 monovalent vaccine to assess for potential vaccine safety problems.
STUDY DESIGN: We reviewed reports of adverse events (AEs) in pregnant women who received 2009-H1N1 vaccines from Oct. 1, 2009,
through Feb. 28, 2010.
RESULTS: VAERS received294 reports of AEs in pregnant women who received 2009-H1N1 vaccine: 288 after inactivated and 6 after the live attenuated vaccines. Two maternal deaths were reported. Fifty-nine women (20.1%) were hospitalized. We verified 131 pregnancy-specific outcomes: 95 spontaneous abortions (20 weeks or less); 18 stillbirths(greater than or equal to 20 weeks); 7 preterm deliveries(less than 37 weeks); 3 threatened abortions; 2 preterm labor; 2 preeclampsia; and 1 each of fetal hydronephrosis, fetal
tachycardia, intrauterine growth ******ation, and cleft lip.
CONCLUSION: Review of reports to VAERS following H1N1 vaccination in pregnant women did not identify any concerning patterns of maternal or fetal outcomes.
Moro PL, Broder K, Zheteyeva Y, et al. “Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009”. American Journal of Obstetrics & Gynecology 204:146.e1-7 (2011).
ABSTRACT:
OBJECTIVE: The objective of the study was to characterize reports to the Vaccine Adverse Event Reporting System (VAERS) in pregnant
women who received seasonal influenza vaccines to assess for potential vaccine safety concerns.
STUDY DESIGN: We searched VAERS for reports of adverse events (AEs) in pregnant women who received trivalent inactivated influenza vaccine (TIV) from July 1, 1990 through June 30, 2009, or live attenuated influenza vaccine (LAIV) from July 1, 2003, through June 30, 2009.
RESULTS: A total of 148 reports after TIV and 27 reports after LAIV were identified. Twenty TIV (13.5%) and 1 LAIV (4%) reports were classified as serious. No specific AEs were reported in 30 TIV (20.3%) and 16 LAIV (59%) reports. The most common pregnancy-specific AE was spontaneous abortion: 17 after TIV (11.5%) and 3 after LAIV (11%). The reporting rate of spontaneous abortion was 1.9 per million pregnant women vaccinated.
CONCLUSION: No unusual patterns of pregnancy complications or fetal outcomes were observed in the VAERS reports of pregnant women after
the administration of TIV or LAIV.
Christian, Lisa M., Jay D. Iams, Kyle Porter, and Ronald Glaser. “Inflammatory responses to trivalent influenza virus vaccine among pregnant women.” Vaccine (2011).
ABSTRACT:
Objective
In the U.S., seasonal trivalent influenza virus vaccine (TIV) is currently universally recommended for all pregnant women. However, data on the maternal inflammatory response to vaccination is lacking and would better delineate the safety and clinical utility of immunization. In addition, for research purposes, vaccination has been used as a mild immune trigger to examine in vivo inflammatory responses in nonpregnant adults. The utility of such a model in pregnancy is unknown. Given the clinical and empirical justifications, the current study examined the magnitude, time course, and variance in inflammatory responses following seasonal influenza virus vaccination among pregnant women.
Methods
Women were assessed prior to and at one day (n = 15), two days (n = 10), or approximately one week (n = 21) following TIV. Serum interleukin (IL)-6, tumor necrosis factor (TNF)-α, C-reactive protein (CRP), and macrophage migration inhibitory factor (MIF) were determined by high sensitivity immunoassay.
Results
Significant increases in CRP were seen at one and two days post-vaccination (ps < 05). A similar effect was seen for TNF-α, for which an increase at two days post-vaccination approached statistical significance (p = .06). There was considerable variability in magnitude of response; coefficients of variation for change at two days post-vaccination ranged from 122% to 728%, with the greatest variability in IL-6 responses at this timepoint.
Conclusions
Trivalent influenza virus vaccination elicits a measurable inflammatory response among pregnant women. There is sufficient variability in response for testing associations with clinical outcomes. As adverse perinatal health outcomes including preeclampsia and preterm birth have an inflammatory component, a tendency toward greater inflammatory responding to immune triggers may predict risk of adverse outcomes, providing insight into biological mechanisms underlying risk.The inflammatory response elicited by vaccination is substantially milder and more transient than seen in infectious illness, arguing for the clinical value of vaccination. However, further research is needed to confirm that the mild inflammatory response elicited by vaccination is benign in pregnancy.
The KNOWN risks of getting the flu while pregnant include:
-Higher chance of developing pneumonia (always a risk anyway)
-Higher chance of dying as a result of serious illness (flu or pneumonia, always a risk anyway)
-Higher chance of preterm labor
-Slightly higher chance of fetal deformities
-------
I'm still researching this but wanted to share what I've found so far. If you have QUESTIONS or CONCERNS, please post them..I don't need to hear how I'm just scaring people. What definitely scares me is that these vaccines are RECOMMENDED to ALL pregnant women despite not being proven safe.
I’m probably going to get a lot of crap for posting this and “scaring” people, but I’ve been thinking about doing this for a while now. I should have done this earlier. My goal is NOT to scare you- so if you’ve already had the shot, PLEASE don’t read this. My goal is to help those who haven’t had the shot make an informed decision about getting it. Here are all the FACTS that your doctor may or may not tell you. I’m a librarian and this information is the result of long hours of research. I’ve given links to all my (online) sources so you can read the information first hand, but it’s all here, too.
Approved vaccines for the U.S.: https://www.cdc.gov/flu/protect/vaccine/vaccines.htm
-FLUZONE: “Pregnancy Category B: A developmental and reproductive toxicity study has been performed in female rabbits at a dose approximately 20 times the human dose (on a mg/kg basis) and has revealed no evidence of impaired female fertility or harm to the fetus due to Fluzone Intradermal. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Fluzone Intradermal should be used during pregnancy only if clearly needed.” https://www.fda.gov/downloads/biologicsbloodvaccines/.../ucm195479.pdf
-FLUVIRIN: “Pregnancy Cetgory C: Animal reproduction studies have not been conducted with FLUVIRIN. It is also not known whether FLUVIRIN can cause fetal harm when administered to pregnant women or can affect reproduction capacity. FLUVIRIN should be given to pregnant women only if clearly needed.” https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm123694.pdf
-FLUARIX: “Pregnancy Category B: A reproductive and developmental toxicity study has been performed in female rats at a dose approximately 56 times the human dose (on a mg/kg basis) and revealed no evidence of impaired female fertility or harm to the fetus due to FLUARIX. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, FLUARIX should be given to a pregnant woman only if clearly needed.
In a reproductive and developmental toxicity study, the effect of FLUARIX on embryo-fetal and pre-weaning development was evaluated in pregnant rats. Animals were administered FLUARIX by intramuscular injection once prior to gestation, and during the period of organogenesis (gestation days 6, 8, 11, and 15), 0.1 mL/rat/occasion (approximately 56-fold excess relative to the projected human dose on a body weight basis). No adverse effects on mating, female fertility, pregnancy, parturition, lactation parameters, and embryo-fetal or pre-weaning development were observed. There were no vaccine-related fetal malformations or other evidence of teratogenesis.
Pregnancy Registry: GlaxoSmithKline maintains a surveillance registry to collect data on pregnancy outcomes and newborn health status outcomes following vaccination with FLUARIX during pregnancy. Women who receive FLUARIX during pregnancy should be encouraged to contact GlaxoSmithKline directly or their healthcare provider should contact GlaxoSmithKline by calling 1-888-452-9622.” https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220624.pdf
-FLULAVAL: Pregnancy Category B: A reproductive and developmental toxicity study has been performed in female rats at a dose approximately 56 times the human dose (on a mg/kg basis) and revealed no evidence of impaired female fertility or harm to the fetus due to FLULAVAL. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, FLULAVAL should be given to a pregnant woman only if clearly needed.
In a reproductive and developmental toxicity study, the effect of FLULAVAL on embryo-fetal and pre-weaning development was evaluated in pregnant rats. Animals were administered FLULAVAL by intramuscular injection once prior to gestation, and during the period of organogenesis (gestation days 6, 8, 11, and 15), 0.1 mL/rat/occasion (approximately 56-fold excess relative to the projected human dose on a body weight basis). No adverse effects on mating, female fertility, pregnancy, parturition, lactation parameters, and embryo-fetal or pre-weaning development were observed. There were no vaccine-related fetal malformations or other evidence of teratogenesis.
Pregnancy Registry: GlaxoSmithKline maintains a surveillance registry to collect data on pregnancy outcomes and newborn health status outcomes following vaccination with FLULAVAL during pregnancy. Women who receive FLULAVAL during pregnancy should be encouraged to contact GlaxoSmithKline directly or their healthcare provider should contact GlaxoSmithKline by calling 1-888-452-9622.” https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112904.pdf
-AFLURIA: “Pregnancy Category C: Animal reproduction studies have not been conducted with AFLURIA. It is also not known whether AFLURIA can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. AFLURIA should be given to a pregnant woman only if clearly needed.” https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm220730.pdf
-FLUMISTA: “Pregnancy Category C: Animal reproduction studies have not been conducted with FluMist. It is not known whether FluMist can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. FluMist should be given to a pregnant woman only if clearly needed. The effect of the vaccine on embryo-fetal and pre-weaning development was evaluated in a developmental toxicity study using pregnant rats receiving the frozen formulation. Groups of animals were administered the vaccine either once (during the period of organogenesis on gestation day 6) or twice (prior to gestation and during the period of organogenesis on gestation day 6), 250 microliter/rat/occasion (approximately 110-140 human dose equivalents), by intranasal instillation. No adverse effects on pregnancy, parturition, lactation, embryo-fetal or pre-weaning development were observed. There were no vaccine-related fetal malformations or other evidence of teratogenesis noted in this study.” https://www.medimmune.com/pdf/products/flumist_pi.pdf
Approved vaccines for the U.K.:
-PANDEMRIX: Pregnancy and lactation: Pandemrix has been administered to women in each trimester of pregnancy. Information on outcomes from estimated more than 200,000 women who have been vaccinated during pregnancy is currently limited. There was no evidence of an increased risk of adverse outcomes in over 100 pregnancies that were followed in a prospective clinical study.
Animal studies with Pandemrix do not indicate reproductive toxicity (see section 5.3).
Data from pregnant women vaccinated with different inactivated non-adjuvanted seasonal vaccines do not suggest malformations or fetal or neonatal toxicity.
Pandemrix may be administered in lactating women.” https://www.emea.europa.eu/docs/en_...duct_Information/human/000832/WC500038121.pdf
-FOCETRIA: Pregnancy and lactation: It is estimated that more than 90,000 women have been vaccinated during pregnancy with Focetria H1N1v. However information on the number of outcomes is currently limited. Preliminary data on outcomes from spontaneously reported events and ongoing post-marketing studies (pregnancy registry and prospective interventional study) do not suggest direct or indirect harmful effects with respect to pregnancy.
Data from pregnant women vaccinated with different inactivated non-adjuvanted seasonal vaccines do not suggest malformations or fetal or neonatal toxicity. An animal study with H5N1 mock-up vaccine did not indicate reproductive toxicity (see section 5.3). The use of Focetria during pregnancy has to take into account official recommendations. Focetria may be administered to lactacting women. https://www.ema.europa.eu/docs/en_G...duct_Information/human/000710/WC500023749.pdf
Peer-reviewed articles related to fetal harm and the vaccine OR showing no relationship between the two:
Moro, Pedro L. et al. “Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System”. American Journal of Obstetrics & Gynecology (2011).
ABSTRACT:
OBJECTIVE: The objective of the study was to evaluate and summarize reports to the Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting system, in pregnant women who received influenza A (H1N1) 2009 monovalent vaccine to assess for potential vaccine safety problems.
STUDY DESIGN: We reviewed reports of adverse events (AEs) in pregnant women who received 2009-H1N1 vaccines from Oct. 1, 2009,
through Feb. 28, 2010.
RESULTS: VAERS received294 reports of AEs in pregnant women who received 2009-H1N1 vaccine: 288 after inactivated and 6 after the live attenuated vaccines. Two maternal deaths were reported. Fifty-nine women (20.1%) were hospitalized. We verified 131 pregnancy-specific outcomes: 95 spontaneous abortions (20 weeks or less); 18 stillbirths(greater than or equal to 20 weeks); 7 preterm deliveries(less than 37 weeks); 3 threatened abortions; 2 preterm labor; 2 preeclampsia; and 1 each of fetal hydronephrosis, fetal
tachycardia, intrauterine growth ******ation, and cleft lip.
CONCLUSION: Review of reports to VAERS following H1N1 vaccination in pregnant women did not identify any concerning patterns of maternal or fetal outcomes.
Moro PL, Broder K, Zheteyeva Y, et al. “Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009”. American Journal of Obstetrics & Gynecology 204:146.e1-7 (2011).
ABSTRACT:
OBJECTIVE: The objective of the study was to characterize reports to the Vaccine Adverse Event Reporting System (VAERS) in pregnant
women who received seasonal influenza vaccines to assess for potential vaccine safety concerns.
STUDY DESIGN: We searched VAERS for reports of adverse events (AEs) in pregnant women who received trivalent inactivated influenza vaccine (TIV) from July 1, 1990 through June 30, 2009, or live attenuated influenza vaccine (LAIV) from July 1, 2003, through June 30, 2009.
RESULTS: A total of 148 reports after TIV and 27 reports after LAIV were identified. Twenty TIV (13.5%) and 1 LAIV (4%) reports were classified as serious. No specific AEs were reported in 30 TIV (20.3%) and 16 LAIV (59%) reports. The most common pregnancy-specific AE was spontaneous abortion: 17 after TIV (11.5%) and 3 after LAIV (11%). The reporting rate of spontaneous abortion was 1.9 per million pregnant women vaccinated.
CONCLUSION: No unusual patterns of pregnancy complications or fetal outcomes were observed in the VAERS reports of pregnant women after
the administration of TIV or LAIV.
Christian, Lisa M., Jay D. Iams, Kyle Porter, and Ronald Glaser. “Inflammatory responses to trivalent influenza virus vaccine among pregnant women.” Vaccine (2011).
ABSTRACT:
Objective
In the U.S., seasonal trivalent influenza virus vaccine (TIV) is currently universally recommended for all pregnant women. However, data on the maternal inflammatory response to vaccination is lacking and would better delineate the safety and clinical utility of immunization. In addition, for research purposes, vaccination has been used as a mild immune trigger to examine in vivo inflammatory responses in nonpregnant adults. The utility of such a model in pregnancy is unknown. Given the clinical and empirical justifications, the current study examined the magnitude, time course, and variance in inflammatory responses following seasonal influenza virus vaccination among pregnant women.
Methods
Women were assessed prior to and at one day (n = 15), two days (n = 10), or approximately one week (n = 21) following TIV. Serum interleukin (IL)-6, tumor necrosis factor (TNF)-α, C-reactive protein (CRP), and macrophage migration inhibitory factor (MIF) were determined by high sensitivity immunoassay.
Results
Significant increases in CRP were seen at one and two days post-vaccination (ps < 05). A similar effect was seen for TNF-α, for which an increase at two days post-vaccination approached statistical significance (p = .06). There was considerable variability in magnitude of response; coefficients of variation for change at two days post-vaccination ranged from 122% to 728%, with the greatest variability in IL-6 responses at this timepoint.
Conclusions
Trivalent influenza virus vaccination elicits a measurable inflammatory response among pregnant women. There is sufficient variability in response for testing associations with clinical outcomes. As adverse perinatal health outcomes including preeclampsia and preterm birth have an inflammatory component, a tendency toward greater inflammatory responding to immune triggers may predict risk of adverse outcomes, providing insight into biological mechanisms underlying risk.The inflammatory response elicited by vaccination is substantially milder and more transient than seen in infectious illness, arguing for the clinical value of vaccination. However, further research is needed to confirm that the mild inflammatory response elicited by vaccination is benign in pregnancy.
The KNOWN risks of getting the flu while pregnant include:
-Higher chance of developing pneumonia (always a risk anyway)
-Higher chance of dying as a result of serious illness (flu or pneumonia, always a risk anyway)
-Higher chance of preterm labor
-Slightly higher chance of fetal deformities
-------
I'm still researching this but wanted to share what I've found so far. If you have QUESTIONS or CONCERNS, please post them..I don't need to hear how I'm just scaring people. What definitely scares me is that these vaccines are RECOMMENDED to ALL pregnant women despite not being proven safe.
for me it was "clearly needed" because I am a registered nurse who comes in contact with hundreds of patients a month. It's "clearly needed" to protect me AND those patients I come in contact with. To those who don't feel they need it, that is their opinion and their choice. BUT Herd Immunity is a well proven way to stop the spread deadly diseases (like polio, measles, mumps, rubella etc).
